2 results
Approved WMORecruiting
Primary Objectives:• To assess the safety and tolerability of DCC 3014.• To characterize the pharmacokinetic (PK) profile of DCC 3014.• To determine the maximum tolerated dose (MTD) of DCC 3014.• To determine the recommended Phase 2 dose (RP2D) of…
Approved WMOPending
Phase I:Primary Objective:To determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK-positive solid tumors RP2D and, if applicable, the MTD as determined by incidence of DLTs during Cycle 1, overall safety profile, PK…